{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T08:41:28Z","timestamp":1782981688927,"version":"3.54.5"},"reference-count":55,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1124\/jpet.118.248492","type":"journal-article","created":{"date-parts":[[2018,4,26]],"date-time":"2018-04-26T17:45:19Z","timestamp":1524764719000},"page":"113-124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["3,4-Dihydroxyphenylacetaldehyde-Induced Protein Modifications and Their Mitigation by N-Acetylcysteine"],"prefix":"10.1016","volume":"366","author":[{"given":"Yunden","family":"Jinsmaa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehonatan","family":"Sharabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patti","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risa","family":"Isonaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.118.248492_bib1","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1021\/acs.chemrestox.5b00528","article-title":"Antioxidant-mediated modulation of protein reactivity for 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite","volume":"29","author":"Anderson","year":"2016","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/jpet.118.248492_bib2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3389\/fnagi.2014.00197","article-title":"Structure activity relationship of phenolic acid inhibitors of \u03b1-synuclein fibril formation and toxicity","volume":"6","author":"Ardah","year":"2014","journal-title":"Front Aging Neurosci"},{"key":"10.1124\/jpet.118.248492_bib3","first-page":"878935","article-title":"Dopamine cytotoxicity involves both oxidative and nonoxidative pathways in SH-SY5Y cells: potential role of alpha-synuclein overexpression and proteasomal inhibition in the etiopathogenesis of Parkinson\u2019s disease","volume":"2014","author":"Banerjee","year":"2014","journal-title":"Parkinsons Dis"},{"key":"10.1124\/jpet.118.248492_bib4","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00401-007-0303-9","article-title":"Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine","volume":"115","author":"Burke","year":"2008","journal-title":"Acta Neuropathol"},{"key":"10.1124\/jpet.118.248492_bib5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0006-8993(03)03354-7","article-title":"3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson\u2019s disease pathogenesis","volume":"989","author":"Burke","year":"2003","journal-title":"Brain Res"},{"key":"10.1124\/jpet.118.248492_bib6","doi-asserted-by":"crossref","first-page":"e34713","DOI":"10.1371\/journal.pone.0034713","article-title":"Differential effects of UCHL1 modulation on alpha-synuclein in PD-like models of alpha-synucleinopathy","volume":"7","author":"Cartier","year":"2012","journal-title":"PLoS One"},{"key":"10.1124\/jpet.118.248492_bib7","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1021\/tx5002223","article-title":"Benomyl, aldehyde dehydrogenase, DOPAL, and the catecholaldehyde hypothesis for the pathogenesis of Parkinson\u2019s disease","volume":"27","author":"Casida","year":"2014","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/jpet.118.248492_bib8","doi-asserted-by":"crossref","first-page":"8138","DOI":"10.1523\/JNEUROSCI.0319-07.2007","article-title":"Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration","volume":"27","author":"Caudle","year":"2007","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.118.248492_bib9","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/j.1471-4159.2009.06191.x","article-title":"Relationship between alpha synuclein phosphorylation, proteasomal inhibition and cell death: relevance to Parkinson\u2019s disease pathogenesis","volume":"110","author":"Chau","year":"2009","journal-title":"J Neurochem"},{"key":"10.1124\/jpet.118.248492_bib10","first-page":"E1994","article-title":"Structural characterization of toxic oligomers that are kinetically trapped during \u03b1-synuclein fibril formation","volume":"112","author":"Chen","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.118.248492_bib11","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.expneurol.2014.09.016","article-title":"Neuroprotective effects of aldehyde dehydrogenase 2 activation in rotenone-induced cellular and animal models of parkinsonism","volume":"263","author":"Chiu","year":"2015","journal-title":"Exp Neurol"},{"key":"10.1124\/jpet.118.248492_bib12","doi-asserted-by":"crossref","first-page":"4486","DOI":"10.1074\/jbc.M117.813865","article-title":"The small heat shock protein Hsp27 binds \u03b1-synuclein fibrils, preventing elongation and cytotoxicity","volume":"293","author":"Cox","year":"2018","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.118.248492_bib13","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.neubiorev.2015.04.015","article-title":"Clinical trials of N-acetylcysteine in psychiatry and neurology: a systematic review","volume":"55","author":"Deepmala","year":"2015","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1124\/jpet.118.248492_bib14","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1750-3639.1999.tb00553.x","article-title":"Multiple system atrophy: a sporadic synucleinopathy","volume":"9","author":"Dickson","year":"1999","journal-title":"Brain Pathol"},{"key":"10.1124\/jpet.118.248492_bib15","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/S0002-9440(10)65226-1","article-title":"Widespread alterations of alpha-synuclein in multiple system atrophy","volume":"155","author":"Dickson","year":"1999","journal-title":"Am J Pathol"},{"key":"10.1124\/jpet.118.248492_bib16","doi-asserted-by":"crossref","first-page":"27660","DOI":"10.1074\/jbc.M115.686584","article-title":"Oligomerization and membrane-binding properties of covalent adducts formed by the interaction of \u03b1-synuclein with the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde (DOPAL)","volume":"290","author":"Follmer","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.118.248492_bib17","doi-asserted-by":"crossref","DOI":"10.1111\/febs.14393","article-title":"The role of glucocerebrosidase in Parkinson disease pathogenesis","author":"Gegg","year":"2018","journal-title":"FEBS J"},{"key":"10.1124\/jpet.118.248492_bib18","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00401-010-0741-7","article-title":"Glucocerebrosidase is present in \u03b1-synuclein inclusions in Lewy body disorders","volume":"120","author":"Goker-Alpan","year":"2010","journal-title":"Acta Neuropathol"},{"key":"10.1124\/jpet.118.248492_bib19","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1124\/jpet.115.230201","article-title":"Comparison of monoamine oxidase inhibitors in decreasing production of the autotoxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells","volume":"356","author":"Goldstein","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.118.248492_bib20","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1007\/s11064-017-2371-0","article-title":"N-Acetylcysteine prevents the increase in spontaneous oxidation of dopamine during monoamine oxidase inhibition in PC12 cells","volume":"42","author":"Goldstein","year":"2017","journal-title":"Neurochem Res"},{"key":"10.1124\/jpet.118.248492_bib21","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.pharmthera.2014.06.006","article-title":"Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders","volume":"144","author":"Goldstein","year":"2014","journal-title":"Pharmacol Ther"},{"key":"10.1124\/jpet.118.248492_bib22","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/jnc.13042","article-title":"Rotenone decreases intracellular aldehyde dehydrogenase activity: implications for the pathogenesis of Parkinson\u2019s disease","volume":"133","author":"Goldstein","year":"2015","journal-title":"J Neurochem"},{"key":"10.1124\/jpet.118.248492_bib23","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/j.1471-4159.2012.07924.x","article-title":"Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson\u2019s disease","volume":"123","author":"Goldstein","year":"2012","journal-title":"J Neurochem"},{"key":"10.1124\/jpet.118.248492_bib24","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1468-1331.2010.03246.x","article-title":"Catechols in post-mortem brain of patients with Parkinson disease","volume":"18","author":"Goldstein","year":"2011","journal-title":"Eur J Neurol"},{"key":"10.1124\/jpet.118.248492_bib25","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.parkreldis.2015.03.006","article-title":"Decreased vesicular storage and aldehyde dehydrogenase activity in multiple system atrophy","volume":"21","author":"Goldstein","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1124\/jpet.118.248492_bib26","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.parkreldis.2016.12.011","article-title":"Determinants of denervation-independent depletion of putamen dopamine in Parkinson\u2019s disease and multiple system atrophy","volume":"35","author":"Goldstein","year":"2017","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1124\/jpet.118.248492_bib27","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/jnc.12345","article-title":"Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson\u2019s disease","volume":"126","author":"Goldstein","year":"2013","journal-title":"J Neurochem"},{"key":"10.1124\/jpet.118.248492_bib28","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/jnc.12766","article-title":"A vesicular sequestration to oxidative deamination shift in myocardial sympathetic nerves in Parkinson\u2019s disease","volume":"131","author":"Goldstein","year":"2014","journal-title":"J Neurochem"},{"key":"10.1124\/jpet.118.248492_bib29","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev.biochem.67.1.425","article-title":"The ubiquitin system","volume":"67","author":"Hershko","year":"1998","journal-title":"Annu Rev Biochem"},{"key":"10.1124\/jpet.118.248492_bib30","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1146\/annurev.genet.30.1.405","article-title":"Ubiquitin-dependent protein degradation","volume":"30","author":"Hochstrasser","year":"1996","journal-title":"Annu Rev Genet"},{"key":"10.1124\/jpet.118.248492_bib31","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.neulet.2014.03.016","article-title":"Divalent metal ions enhance DOPAL-induced oligomerization of alpha-synuclein","volume":"569","author":"Jinsmaa","year":"2014","journal-title":"Neurosci Lett"},{"key":"10.1124\/jpet.118.248492_bib32","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.autneu.2015.12.008","article-title":"DOPAL is transmissible to and oligomerizes alpha-synuclein in human glial cells","volume":"194","author":"Jinsmaa","year":"2016","journal-title":"Auton Neurosci"},{"key":"10.1124\/jpet.118.248492_bib33","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.mam.2009.04.001","article-title":"The proteasomal system","volume":"30","author":"Jung","year":"2009","journal-title":"Mol Aspects Med"},{"key":"10.1124\/jpet.118.248492_bib34","doi-asserted-by":"crossref","first-page":"10773","DOI":"10.1073\/pnas.1713969114","article-title":"TrkB neurotrophic activities are blocked by \u03b1-synuclein, triggering dopaminergic cell death in Parkinson\u2019s disease","volume":"114","author":"Kang","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.118.248492_bib35","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10930-015-9625-y","article-title":"Alpha-synuclein fibrils interact with dopamine reducing its cytotoxicity on PC12 cells","volume":"34","author":"Khalife","year":"2015","journal-title":"Protein J"},{"key":"10.1124\/jpet.118.248492_bib36","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0891-5849(01)00484-1","article-title":"Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria","volume":"30","author":"Kristal","year":"2001","journal-title":"Free Radic Biol Med"},{"key":"10.1124\/jpet.118.248492_bib37","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0006-8993(00)02309-X","article-title":"3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells","volume":"868","author":"Lamensdorf","year":"2000","journal-title":"Brain Res"},{"key":"10.1124\/jpet.118.248492_bib38","doi-asserted-by":"crossref","first-page":"9977","DOI":"10.1073\/pnas.1402134111","article-title":"Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo","volume":"111","author":"Lohr","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.118.248492_bib39","doi-asserted-by":"crossref","first-page":"5012129","DOI":"10.1155\/2017\/5012129","article-title":"The contribution of \u03b1-synuclein spreading to Parkinson\u2019s disease synaptopathy","volume":"2017","author":"Longhena","year":"2017","journal-title":"Neural Plast"},{"key":"10.1124\/jpet.118.248492_bib40","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/1055-8330(95)90016-0","article-title":"An endogenous dopaminergic neurotoxin: implication for Parkinson\u2019s disease","volume":"4","author":"Mattammal","year":"1995","journal-title":"Neurodegeneration"},{"key":"10.1124\/jpet.118.248492_bib41","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1021\/acs.analchem.5b04420","article-title":"Detection of free and protein-bound ortho-quinones by near-infrared fluorescence","volume":"88","author":"Mazzulli","year":"2016","journal-title":"Anal Chem"},{"key":"10.1124\/jpet.118.248492_bib42","doi-asserted-by":"crossref","first-page":"e0157602","DOI":"10.1371\/journal.pone.0157602","article-title":"N-Acetyl cysteine may support dopamine neurons in Parkinson\u2019s disease: preliminary clinical and cell line data","volume":"11","author":"Monti","year":"2016","journal-title":"PLoS One"},{"key":"10.1124\/jpet.118.248492_bib43","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3233\/JPD-160779","article-title":"Implication of alpha-synuclein phosphorylation at S129 in synucleinopathies: what have we learned in the last decade?","volume":"6","author":"Oueslati","year":"2016","journal-title":"J Parkinsons Dis"},{"key":"10.1124\/jpet.118.248492_bib44","doi-asserted-by":"crossref","first-page":"e15251","DOI":"10.1371\/journal.pone.0015251","article-title":"The neurotoxicity of DOPAL: behavioral and stereological evidence for its role in Parkinson disease pathogenesis","volume":"5","author":"Panneton","year":"2010","journal-title":"PLoS One"},{"key":"10.1124\/jpet.118.248492_bib45","doi-asserted-by":"crossref","first-page":"8210","DOI":"10.1523\/JNEUROSCI.5456-13.2014","article-title":"Is Parkinson\u2019s disease a vesicular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum","volume":"34","author":"Pifl","year":"2014","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.118.248492_bib46","doi-asserted-by":"crossref","first-page":"40699","DOI":"10.1038\/srep40699","article-title":"DOPAL derived alpha-synuclein oligomers impair synaptic vesicles physiological function","volume":"7","author":"Plotegher","year":"2017","journal-title":"Sci Rep"},{"key":"10.1124\/jpet.118.248492_bib47","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the alpha-synuclein gene identified in families with Parkinson\u2019s disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science"},{"key":"10.1124\/jpet.118.248492_bib48","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1021\/tx700248y","article-title":"Lipid peroxidation products inhibit dopamine catabolism yielding aberrant levels of a reactive intermediate","volume":"20","author":"Rees","year":"2007","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/jpet.118.248492_bib49","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1021\/tx9000557","article-title":"Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and the catechol","volume":"22","author":"Rees","year":"2009","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/jpet.118.248492_bib50","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"10.1124\/jpet.118.248492_bib51","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0304-3940(98)00407-8","article-title":"Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy","volume":"249","author":"Wakabayashi","year":"1998","journal-title":"Neurosci Lett"},{"key":"10.1124\/jpet.118.248492_bib52","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.bbrc.2017.04.050","article-title":"Superoxide is the critical driver of DOPAL autoxidation, lysyl adduct formation, and crosslinking of \u03b1-synuclein","volume":"487","author":"Werner-Allen","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/jpet.118.248492_bib53","doi-asserted-by":"crossref","first-page":"e31522","DOI":"10.1371\/journal.pone.0031522","article-title":"Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson\u2019s disease","volume":"7","author":"Wey","year":"2012","journal-title":"PLoS One"},{"key":"10.1124\/jpet.118.248492_bib54","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.expneurol.2010.06.017","article-title":"Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson\u2019s disease brains with and without dementia","volume":"225","author":"Wills","year":"2010","journal-title":"Exp Neurol"},{"key":"10.1124\/jpet.118.248492_bib55","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1073\/pnas.1100976108","article-title":"In vivo demonstration that alpha-synuclein oligomers are toxic","volume":"108","author":"Winner","year":"2011","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524262054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524262054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.118.248492","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T19:59:22Z","timestamp":1739995162000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524262054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0022356524262054"],"URL":"https:\/\/doi.org\/10.1124\/jpet.118.248492","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"3,4-Dihydroxyphenylacetaldehyde-Induced Protein Modifications and Their Mitigation by N-Acetylcysteine","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.118.248492","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"U.S. Government work not protected by U.S. copyright","name":"copyright","label":"Copyright"}]}}